Recent Updates — KZIA
Kazia Therapeutics Limited announced that Sovargen Co., Ltd. has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib for rare seizure disorders, specifically focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggers a $2 million development payment to Kazia under their exclusive licensing agreement entered into in March 2024. The company is also eligible for up to $17 million in additional milestones plus royalties on net sales. Kazia Therapeutics Limited operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology and restore anti-tumor immunity.
On September 1, 2026, Kazia Therapeutics announced preclinical data demonstrating that its lead asset, paxalisib, reduced tumor burden by 52% in microsatellite stable (MSS)/proficient mismatch repair (pMMR) colorectal cancer models and enhanced response to immunotherapy. The company plans to launch a five-arm Phase 2 clinical trial for this indication, with enrollment expected to begin in the first quarter of 2027. Additionally, Kazia reported preclinical evidence that paxalisib resensitized CDK4/6 inhibitor-resistant tumors in HR+/HER2- breast cancer models and announced an expansion of its ongoing triple-negative breast cancer trial to include a three-arm evaluation of paxalisib combinations in this population. First patient enrollment for the breast cancer expansion is targeted before year-end 2026, with full enrollment anticipated by the end of 2027. Kazia Therapeutics operates as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology and restore anti-tumor immunity.
On August 28, 2026, Kazia Therapeutics Limited priced an underwritten public offering of 2,580,000 American Depositary Shares (ADSs), each representing 500 ordinary shares. The offering includes pre-funded warrants to purchase up to 303,200 ADSs and accompanying Series A and Series B Warrants to purchase up to 2,243,478 and 2,064,000 ADSs, respectively. The combined public offering price is $15.50 per ADS and accompanying warrants, generating expected gross proceeds of approximately $40 million for the company. Additional potential gross proceeds of up to $80 million may be realized upon exercise of the Series A and B Warrants at prices of $17.825 and $19.375 per ADS. The net proceeds are intended to fund clinical development of paxalisib, including Phase 1b trials in advanced triple-negative breast cancer and expansions into HR+/HER2- breast cancer, as well as for working capital. The offering closed on or about August 31, 2026. Kazia Therapeutics is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology.
Kazia Therapeutics Limited filed a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of American Depositary Shares under its March 17, 2026 Sales Agreement with Leerink Partners LLC from $100 million to $80 million. This adjustment modifies the existing registration statement on Form F-3 (File No. 333-294392). The company operates in the biotechnology industry, focusing on the development of therapeutic treatments for cancer.